Japan, July 1 -- JANSSEN BIOTECH INC,PROTAGONIST THERAPEUTICS INC has got intellectual property rights for 'PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES.' Other related details are as follows:

Application Number: JP,2023-119000

Category (FI): A61P35/00,A61P29/00,A61P1/04,A61P43/00,111,A61K38/12,C12N15/11@Z,A61P17/06,A61K38/10,C07K7/08,C12N15/63@Z,A61P19/02,A61P37/06,A61P1/18,A61P3/10,A61P1/16,101,A61P11/00,A61P11/02,A61P11/06

Stage: Grant (IP right granted following substantive examination.)

Filing Date: July 21, 2023

Publication Date: Oct. 3, 2023

The original document can be viewed at: https://www.j-platpat.inpit.go.jp/p0100

Disclaimer: Curated by HT Syndication....